RPRX
Royalty Pharma PLC
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2020-06-16
$66.40
-0.12 (-0.18%)
last quote
Want the full multi-source brief on RPRX?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$66.40
High
$67.44
Low
$66.12
Previous close
$66.52
Fundamentals
Market cap
$38.52B
P/E (TTM)
47.27x
P/S (TTM)
15.19x
P/B
3.44x
Gross margin
—
Operating margin
59.61%
Net margin
32.14%
Rev growth (YoY)
10.01%
EPS growth (YoY)
-15.92%
ROE
12.25%
52W high
$67.70
52W low
$36.03
Beta
0.38x
Industry peers
by market cap
Upcoming earnings
next 30 days
2026-11-04todaybefore market
Q3 2026EPS est $1.21Rev est $812.5M
Recent SEC filings
CIK 1802768filing-language history →
Recent news
2026-10-28 → 2026-11-04
Yahoo · 4d
Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision Nears
Zenas BioPharma (NASDAQ:ZBIO) outlined development plans for obexelimab in systemic lupus erythematosus (SLE) and ZB021, an investigational oral IL-17AA/AF inhibitor, during an R&D event ahead of clinical data expected later in the quarter. Founder and Chief Executive Officer Lonnie Moulder sai
Yahoo · 4d
Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key Metrics
Beyond analysts' top-and-bottom-line estimates for Royalty Pharma (RPRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.
Yahoo · 5d
Should You Buy Royalty Pharma Stock Before Nov. 4?
Don't expect earnings day to sustain the stock's recent rally.
Yahoo · 5d
Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · 6d
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · 6d
Funds Load Up On Marriott, Estee Lauder As Big Tech Earnings Loom
Funds played defense as they load up on Marriott, Estee Lauder and biotech and energy names in Tuesday's stock market.
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial